Skip to main content

Table 1 Demographic and baseline characteristics of patients

From: Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study

 BCL high dose, N = 49BCL low dose, N = 47Placebo, N = 45
Age (years)
 Mean (SD)60.9 (9.78)61.4 (7.49)63.3 (7.69)
Sex, n (%)
 Female39 (79.6)40 (85.1)34 (75.6)
BMI (kg/m2)
 Mean (SD)29.4 (4.87)30.4 (5.23)29.4 (5.2)
Time from diagnosis of knee OA (years)
 Mean (SD)7.41 (7.294)6.6 (4.671)7.6 (9.3)
KL grade, n (%)
 Grade I0 (0.0%)0 (0.0%)0 (0.0%)
 Grade II31 (63.3%)27 (57.4%)29 (64.4%)
 Grade III18 (36.7%)19 (40.4%)16 (35.6%)
 Grade IV0 (0.0%)1 (2.0%)0 (0.0%)
Target knee (the most symptomatic), n (%)
 Right27 (55.1%)22 (46.8%)25 (55.6%)
Target knee pain (VAS, mm)
 Mean (SD)62.9 (13.8)63.3 (15.8)59.9 (12.3)
PGADA (VAS, mm)
 Mean (SD)67.2 (17.5)69.6 (17.8)63.9 (17.3)
Coll2-1 (nM)
 Mean (SD)393.39 (165.2)373.8 (133.5)384.7 (122.0)
Ultra-sensitive CRP (mg/l)
 Mean (SD)2.5 (2.5)3.4 (2.9)3.2 (2.8)
Rescue treatment (NSAIDs) in the last month, n (%)
 No15 (30.6%)12 (25.5%)13 (28.9%)
 Less than 7 days5 (10.2%)2 (4.3%)2 (4.4%)
 7 to 14 days15 (30.6%)19 (40.4%)16 (35.6%)
 15 to 21 days4 (8.2%)9 (19.1%)5 (11.1%)
 More than 21 days7 (14.3%)2 (4.3%)6 (13.3%)
 Every day2 (4.1%)3 (6.4%)3 (6.7%)
 NI1 (2.0%)0 (0.0%)0 (0.0%)
Rescue treatment (paracetamol) in the last month, n (%)
 No6 (12.2%)3 (6.4%)2 (4.4%)
 Less than 7 days1 (2.0%)3 (6.4%)2 (4.4%)
 7 to 14 days27 (55.1%)18 (38.3%)21 (46.7%)
 15 to 21 days3 (6.1%)11 (23.4%)8 (17.8%)
 More than 21 days4 (8.2%)6 (12.8%)7 (15.6%)
 Every day8 (16.3%)6 (12.8%)5 (11.1%)
 NI6 (12.2%)3 (6.4%)2 (4.4%)
KOOS—global score
 Mean (SD)199.2 (68.1)201.5 (73.5)197.7 (60.0)
KOOS—pain
 Mean (SD)45.3 (16.4)45.8 (15.6)44.2 (13.9)
KOOS—ADL
 Mean (SD)49.8 (17.9)48.9 (17.3)48.9 (16.6)
KOOS—QoL
 Mean (SD)32.0 (18.7)31.5 (19.2)33.3 (18.1)
KOOS—symptoms
 Mean (SD)52.15 (15.9)52.8 (15.6)54.1 (13.5)
KOOS—Sport and rec.
 Mean (SD)19.5 (17.1)19.8 (19.8)17.2 (14.5)
  1. ADL activity of daily life, BMI Body Mass Index, NSAID non-steroidal anti-inflammatory drug, KL Kellgren-Lawrence, NI no information, OA osteoarthritis, PAGDA Patient Global Assessment of Disease Activity, QoL Quality of life, SD Standard Deviation, VAS Visual Analog Scale